Click here to view online. Add this email to your safelist.

AstraZeneca logo

Lynparza significantly delays disease progression in Phase III 1st-line SOLO-1 trial for ovarian cancer

27 June 2018

AstraZeneca and Merck & Co., Inc., Kenilworth, N.J., US (Merck: known as MSD outside the US and Canada) today announced positive results from the randomised, double-blinded, placebo-controlled, Phase III SOLO-1 trial of Lynparza (olaparib) tablets.

Read more  Read more

RSS Feed  RSS Feed Twitter  Follow us on Twitter LinkedIn  Follow us on LinkedIn
Legal notice and Terms of Use Privacy policy Cookie policy Site map © AstraZeneca 2018

For more information please visit astrazeneca.com.

If you would like to unsubscribe please click here.